- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02516358
Glycaemic Alterations in ICU
Glycaemic Alterations in ICU: an Observational, Prospective Cohort Study
Przegląd badań
Status
Warunki
Szczegółowy opis
The aim of this study is to determine the local prevalence of critical illness-associated hyperglycaemia (CIAH) and recognised and unrecognised diabetes, as well as to evaluate how premorbid glycaemia impacts the relationship between three glycaemic domains and mortality.
The investigators will calculate the Time In Range (TIR, 70-180 mg/dl) and evaluate distribution of percentage time in range for non-diabetics and diabetics patients, in order to understand the association between TIR and survival in both groups of patients (patients with diabetes and patients without diabetes).
In view of the potential adverse effects of hyperglycaemia, hypoglycaemia and glycaemic variability on the brain, the investigators will dose Neuron Specific Enolase in critically ill patients.
The aim is to define if a biochemical correlation does exist between critically ill dysglycaemia and NSE plasma concentration.
Typ studiów
Zapisy (Oczekiwany)
Kontakty i lokalizacje
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- ICU patients
- expected ICU length of stay > 48 hours
Exclusion Criteria:
- age <18 years
- ICU length of stay <48 hours
- diabetic ketoacidosis
- hyperosmolar nonketonic hyperglycaemia syndrome
- pregnancy
- hypoglycaemic coma
- acute or acute on chronic liver failure, liver transplantation or end-stage liver disease.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Change in glycaemic blood levels during ICU stay
Ramy czasowe: Glycaemic values expressed as mean glycaemia will be collected at the baseline and every 8 hours for the duration of ICU stay, expected average of 10 days per patient.
|
Glycaemic values expressed as mean glycaemia will be collected at the baseline and every 8 hours for the duration of ICU stay, expected average of 10 days per patient.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Episodes of hypoglicaemia (number)
Ramy czasowe: For the duration of ICU stay, expected average of 10 days per patient.
|
For the duration of ICU stay, expected average of 10 days per patient.
|
|
Episodes of hyperglycaemia (number)
Ramy czasowe: For the duration of ICU stay, expected average of 10 days per patient.
|
For the duration of ICU stay, expected average of 10 days per patient.
|
|
Coefficient of variation of blood glucose levels
Ramy czasowe: Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient.
|
Coefficient of Variation, calculated as a percentage
|
Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient.
|
Time in glycaemic Range (TIR)
Ramy czasowe: Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient.
|
Evaluated in hours TIR/ total hours in ICU; calculated as a percentage
|
Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient.
|
Days of mechanical ventilation
Ramy czasowe: Participants will be followed for the duration of ICU stay, expected average per patient: 10 days
|
Participants will be followed for the duration of ICU stay, expected average per patient: 10 days
|
|
Days of continuous renal replacement therapy
Ramy czasowe: Participants will be followed for the duration of ICU stay, expected average per patient: 10 days
|
Participants will be followed for the duration of ICU stay, expected average per patient: 10 days
|
|
Neuron Specific Enolase (NSE) blood levels and glycaemic disorders
Ramy czasowe: NSE collection: Time point A: ICU admission. Time point NSE: 48-72 hours after ICU admission
|
To detect a correlation between NSE levels and glycaemic alterations in both diabetic and non diabetic patients.
|
NSE collection: Time point A: ICU admission. Time point NSE: 48-72 hours after ICU admission
|
Współpracownicy i badacze
Publikacje i pomocne linki
Publikacje ogólne
- Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009 May 23;373(9677):1798-807. doi: 10.1016/S0140-6736(09)60553-5.
- NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97. doi: 10.1056/NEJMoa0810625. Epub 2009 Mar 24.
- Cely CM, Arora P, Quartin AA, Kett DH, Schein RM. Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest. 2004 Sep;126(3):879-87. doi: 10.1378/chest.126.3.879.
- Kalfon P, Le Manach Y, Ichai C, Brechot N, Cinotti R, Dequin PF, Riu-Poulenc B, Montravers P, Annane D, Dupont H, Sorine M, Riou B; CGAO-REA Study Group. Severe and multiple hypoglycemic episodes are associated with increased risk of death in ICU patients. Crit Care. 2015 Apr 8;19(1):153. doi: 10.1186/s13054-015-0851-7.
- Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Hegarty C, Bailey M. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med. 2008 Aug;36(8):2249-55. doi: 10.1097/CCM.0b013e318181039a.
- Krinsley JS, Egi M, Kiss A, Devendra AN, Schuetz P, Maurer PM, Schultz MJ, van Hooijdonk RT, Kiyoshi M, Mackenzie IM, Annane D, Stow P, Nasraway SA, Holewinski S, Holzinger U, Preiser JC, Vincent JL, Bellomo R. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care. 2013 Mar 1;17(2):R37. doi: 10.1186/cc12547.
- Plummer MP, Bellomo R, Cousins CE, Annink CE, Sundararajan K, Reddi BA, Raj JP, Chapman MJ, Horowitz M, Deane AM. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. Intensive Care Med. 2014 Jul;40(7):973-80. doi: 10.1007/s00134-014-3287-7. Epub 2014 Apr 24.
- Sulter G, Elting JW, De Keyser J. Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke. Neurosci Lett. 1998 Aug 28;253(1):71-3. doi: 10.1016/s0304-3940(98)00595-3.
- Krinsley JS, Meyfroidt G, van den Berghe G, Egi M, Bellomo R. The impact of premorbid diabetic status on the relationship between the three domains of glycemic control and mortality in critically ill patients. Curr Opin Clin Nutr Metab Care. 2012 Mar;15(2):151-60. doi: 10.1097/MCO.0b013e32834f0009.
- Krinsley JS, Preiser JC. Time in blood glucose range 70 to 140 mg/dl >80% is strongly associated with increased survival in non-diabetic critically ill adults. Crit Care. 2015 Apr 20;19(1):179. doi: 10.1186/s13054-015-0908-7.
- Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care. 2008 Apr;14(2):135-41. doi: 10.1097/MCC.0b013e3282f57564.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- Gly 1
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cukrzyca
-
National Center for Research Resources (NCRR)Northwestern UniversityZakończonyMoczówka prosta | Diabetes Insipidus, NeurohypophysealStany Zjednoczone
-
Bruce A. BuckinghamZakończonyCukrzyca typu 1 | Cukrzyca autoimmunologiczna | Cukrzyca młodzieńcza | Cukrzyca, Mellitus, Typ 1Stany Zjednoczone
-
Ferring PharmaceuticalsZakończonyCentralna moczówka prostaJaponia
-
Leiden University Medical CenterZakończonyGruczolak przysadki | Guz przysadki | Diabetes Insipidus Cranial Type | Dokrewny; NiedobórHolandia
-
Universitair Ziekenhuis BrusselZakończonyNefrogenna moczówka prostaBelgia
-
National Center for Research Resources (NCRR)Northwestern UniversityZakończonyDiabetes Insipidus, nefrogenny
-
Elizabeth Austen LawsonJeszcze nie rekrutacjaCentralna moczówka prostaStany Zjednoczone
-
University of Colorado, DenverUniversity of AarhusZakończonyNefrogenna moczówka prostaStany Zjednoczone, Dania
-
Emory UniversityZakończony
-
Lady Davis InstituteZakończonyZastosowanie litu, moczówka prosta nefrogennaKanada